The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Naval DaverThe AML Hub was pleased to speak with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, Which AML patients benefit most from venetoclax treatment?
Which AML patients benefit most from venetoclax treatment?
Daver begins by outlining the major impact made by venetoclax and its combinations in improving patient outcomes. He discusses age, comorbidities, and subtypes as factors to consider when selecting treatments. He highlights the similar response rates and lower toxicity of venetoclax compared to other therapies, such as intensive chemotherapy in NPM1-mutated AML. He goes on to explain instances where venetoclax yields superior outcomes and treatment scenarios for "middle-populations", based on individual patient profiles.